| Budget Amount *help |
¥99,450,000 (Direct Cost: ¥76,500,000、Indirect Cost: ¥22,950,000)
Fiscal Year 2018: ¥19,630,000 (Direct Cost: ¥15,100,000、Indirect Cost: ¥4,530,000)
Fiscal Year 2017: ¥19,240,000 (Direct Cost: ¥14,800,000、Indirect Cost: ¥4,440,000)
Fiscal Year 2016: ¥19,630,000 (Direct Cost: ¥15,100,000、Indirect Cost: ¥4,530,000)
Fiscal Year 2015: ¥19,370,000 (Direct Cost: ¥14,900,000、Indirect Cost: ¥4,470,000)
Fiscal Year 2014: ¥21,580,000 (Direct Cost: ¥16,600,000、Indirect Cost: ¥4,980,000)
|
|---|
| Outline of Final Research Achievements |
A lack of oxygen causes harmful hypoxic stress in cells and organs, while oxygen is also a source of harmful oxidative stressors, including reactive oxygen species. Because oxygen is delivered into every organ by erythrocytes, cellular oxygen levels largely depend on the circulation of erythrocytes. Erythrocyte production is mainly controlled by the erythroid growth factor erythropoietin (Epo) which is secreted by REP (renal Epo producing) cells in a hypoxia-inducible manner. This study elucidated the regulatory mechanism of Epo production in REP cells, and demonstrated that defects in the mechanism are closely associated with the pathogenesis and progression of many types of diseases through the synergistic effects of hypoxic and oxidative stresses. These results confirm that therapeutic strategies targeting the cellular mechanisms of adaptation to hypoxic or oxidative stress, which are currently going on clinical trials, are plausible for treating a variety of diseases.
|
